A Comparison of Apolipoprotein E Polymorphism in Alzheimer’s Disease and Subcortical Vascular Dementia in Koreans
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose The apolipoprotein E (Apo E) ε4 allele is known to be a risk factor for Alzheimer’s disease (AD). However,there are debates about the relationship between Apo E ε4 frequency and subcortical vascular dementia (SVaD). We compared the frequencyof the Apo E ε4 allele in AD and SVaD in Koreans. Methods The study was comprised of 400 subjects who visited the Dementia Clinic at Daegu Catholic University from July 2007 to December2011. Neuropsychological tests, a brain MRI, and blood laboratory tests were performed on all subjects. Two hundred and ninety subjectswere AD, 32 subjects were SVaD and 78 subjects were normal. The diagnosis for SVaD was based on the Diagnostic and Statistical Manual ofMental Disorders, Fourth Edition (DSM-IV) and Erkinjuntti criteria, and the diagnosis for AD was based on the DSM-IV and National Instituteof Neurological and Communicative Disorders and Stroke and Alzheimer’s disease and Related Disorders Association criteria. Apo Epolymorphism was genotyped in all subjects. Results The Apo E ε4 allele frequency was 17.4% in AD, 10.9% in SVaD and 8.3% in the normal group (p=0.03). The odds ratio (OR) afterage adjustment for AD conferred to the Apo E ε4 was 2.04 (p=0.04). But, the OR for SVaD conferred to the Apo E ε4 allele was 1.34 (p=0.62),indicating that the Apo E ε4 allele does not significantly confer the risk of SVaD. Conclusions Apo E ε4 is a reliable predictor of AD but has modest efficacy for predicting SVaD in Koreans.
Abstract
Background and Purpose The apolipoprotein E (Apo E) ε4 allele is known to be a risk factor for Alzheimer’s disease (AD). However,there are debates about the relationship between Apo E ε4 frequency and subcortical vascular dementia (SVaD). We compared the frequencyof the Apo E ε4 allele in AD and SVaD in Koreans. Methods The study was comprised of 400 subjects who visited the Dementia Clinic at Daegu Catholic University from July 2007 to December2011. Neuropsychological tests, a brain MRI, and blood laboratory tests were performed on all subjects. Two hundred and ninety subjectswere AD, 32 subjects were SVaD and 78 subjects were normal. The diagnosis for SVaD was based on the Diagnostic and Statistical Manual ofMental Disorders, Fourth Edition (DSM-IV) and Erkinjuntti criteria, and the diagnosis for AD was based on the DSM-IV and National Instituteof Neurological and Communicative Disorders and Stroke and Alzheimer’s disease and Related Disorders Association criteria. Apo Epolymorphism was genotyped in all subjects. Results The Apo E ε4 allele frequency was 17.4% in AD, 10.9% in SVaD and 8.3% in the normal group (p=0.03). The odds ratio (OR) afterage adjustment for AD conferred to the Apo E ε4 was 2.04 (p=0.04). But, the OR for SVaD conferred to the Apo E ε4 allele was 1.34 (p=0.62),indicating that the Apo E ε4 allele does not significantly confer the risk of SVaD. Conclusions Apo E ε4 is a reliable predictor of AD but has modest efficacy for predicting SVaD in Koreans.
참고문헌 (26)
- 손의주, "알쯔하이머병 환자에서 아포지단백E 유전자형과 혈관성 위험인자와의 관계", 대한신경과학회지, 21(1), pp.41~45 (2003), 대한신경과학회
- Hoshino T, "Gene dose effect of the APOE epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer’s disease", Neurobiol Aging, 23, pp.41~45 (2002)
- Cole GM, "Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro", J Neurosci Res, 57, pp.504~520 (1999)
- Elias MF, "The preclinical phase of alzheimer disease: a 22-year prospective study of the Framingham Cohort", Arch Neurol, 57, pp.808~813 (2000)
- Strittmatter WJ, "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease", Proc Natl Acad Sci U S A, 90, pp.8098~8102 (1993)
- Strittmatter WJ, "Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease", Proc Natl Acad Sci U S A, 91, pp.11183~11186 (1994)
- Handelmann GE, "Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro", J Lipid Res, 33, pp.1677~1688 (1992)
- O’Brien KD, "Apolipoprotein E localization in human coronary atherosclerotic plaques by in situ hybridization and immunohistochemistry and comparison with lipoprotein lipase", Am J Pathol, 144, pp.538~548 (1994)
- Thomas T, "beta-Amyloid-mediated vasoactivity and vascular endothelial damage", Nature, 380, pp.168~171 (1996)
- Kalaria RN, "Apolipoprotein E alleles and brain vascular pathology in Alzheimer’s disease", Ann N Y Acad Sci, 777, pp.266~270 (1996)
- Racchi M, "Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content", Biochem J, 322(Pt 3), pp.893~898 (1997)
- Koudinova NV, "Multiple inhibitory effects of Alzheimer’s peptide Abeta1-40 on lipid biosynthesis in cultured human HepG2 cells", FEBS Lett, 395, pp.204~206 (1996)
- Poirier J, "Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease", Trends Neurosci, 17, pp.525~530 (1994)
- Poirier J, "Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease", Proc Natl Acad Sci U S A, 92, pp.12260~12264 (1995)
- Jarvik GP, "Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study", Neurology, 45, pp.1092~1096 (1995)
- Kao JT, "The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population", Atherosclerosis, 114, pp.55~59 (1995)
- Siest G, "Apolipoprotein E: an important gene and protein to follow in laboratory medicine", Clin Chem, 41(8 Pt 1), pp.1068~1086 (1995)
- Kawamata J, "Apolipoprotein E polymorphism in Japanese patients with Alzheimer’s disease or vascular dementia", J Neurol Neurosurg Psychiatry, 57, pp.1414~1416 (1994)
- Stengård JH, "Apolipoprotein E polymorphism, Alzheimer’s disease and vascular dementia among elderly Finnish men", Acta Neurol Scand, 92, pp.297~298 (1995)
- Kálmán J, "Increased apolipoprotein E4 allele frequency is associated with vascular dementia in the Hungarian population", Acta Neurol Scand, 98, pp.166~168 (1998)
- Molero AE, "Modulation by age and gender of risk for Alzheimer’s disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans:findings from the Maracaibo Aging Study", Neurosci Lett, 307, pp.5~8 (2001)
- Kim KW, "Lack of association between apolipoprotein E polymorphism and vascular dementia in Koreans", J Geriatr Psychiatry Neurol, 21, pp.12~17 (2008)
- Kang HU, "Apolipoprotein E ε4 allele frequency in Korean patients with vascular dementia", Dement Neurocogn Disord, 1, pp.34~38 (2002)
- Corder EH, "Protective effect of apolipoprotein E type 2allele for late onset Alzheimer disease", Nat Genet, 7, pp.180~184 (1994)
- Royston MC, "Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down’s syndrome from dementia", Neuroreport, 5, pp.2583~2585 (1994)
- Payami H, "Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women", Am J Hum Genet, 58, pp.803~811 (1996)